Can atovaquone or azithromycin cause renal toxicity or stress on the kidneys?

Can Atovaquone or Azithromycin Cause Kidney Stress?

Neither atovaquone nor azithromycin directly cause significant renal toxicity or stress on the kidneys, and both can be safely used in patients with renal impairment without dose adjustment.

Azithromycin and Kidney Function

Azithromycin is not nephrotoxic and does not require dose adjustment in renal failure. The FDA label for azithromycin lists multiple adverse effects including gastrointestinal symptoms, cardiac effects (QT prolongation), and hepatotoxicity, but does not identify renal toxicity as a concern 1.

Key pharmacokinetic evidence:

• A dedicated study in patients with varying degrees of renal insufficiency found that neither the area under the curve, distribution volume, nor maximum plasma concentration were affected by renal impairment 2
• The dosage regimen in renal impairment should be the same as in patients with normal renal function 2
• Post-marketing surveillance identified rare cases of interstitial nephritis and acute renal failure, but these are exceedingly uncommon 1

Important distinction: While azithromycin is mentioned in guidelines as a macrolide that does NOT cause the problematic drug interactions seen with clarithromycin or erythromycin (which can lead to rhabdomyolysis and AKI when combined with statins), this actually highlights its safety profile rather than toxicity 3.

Emerging evidence suggests azithromycin may even be protective in certain contexts: In critically ill patients with sepsis-associated acute kidney injury, early azithromycin exposure was independently associated with decreased odds of major adverse kidney events at hospital discharge (adjusted OR 0.62) 4. This protective effect is attributed to its immunomodulatory properties rather than direct renal effects.

Atovaquone and Kidney Function

Atovaquone is not nephrotoxic and is actually preferred in patients with renal impairment when alternatives like trimethoprim-sulfamethoxazole are contraindicated. The FDA label explicitly states that the pharmacokinetics of atovaquone have not been studied in patients with hepatic or renal impairment because it is not renally eliminated 5.

Key pharmacokinetic evidence:

• Greater than 94% of atovaquone is excreted unchanged in feces, not through the kidneys 5
• Atovaquone is extensively protein-bound (99.9%) and undergoes minimal metabolism 5
• In renal transplant recipients, atovaquone demonstrated good tolerability with no cases of Pneumocystis pneumonia and comparable rates of adverse events to other prophylactic agents 6

Clinical practice pattern: Renal impairment is actually listed as one of the indications for choosing atovaquone over trimethoprim-sulfamethoxazole for Pneumocystis prophylaxis 7. This reflects its safety profile in patients with compromised kidney function.

Guideline Context on Nephrotoxins

Current KDIGO guidelines emphasize that not all drugs affecting serum creatinine are truly nephrotoxic 8. The term "nephrotoxic" encompasses both:

1. Drugs causing direct tubular/glomerular injury
2. Drugs causing hemodynamic changes affecting kidney function

Neither azithromycin nor atovaquone falls into these categories. The guidelines specifically note that some drugs causing creatinine elevation (like ACE inhibitors) are actually renoprotective 8.

Common Pitfalls to Avoid

• Do not confuse azithromycin with other macrolides: Clarithromycin and erythromycin cause CYP3A4 interactions leading to nephrotoxicity through secondary mechanisms (e.g., statin-induced rhabdomyolysis), but azithromycin does not 3
• Do not withhold these medications due to renal concerns: Guidelines emphasize that potentially nephrotoxic medications should not be withheld in life-threatening conditions, and these drugs don't even meet that threshold 8
• Monitor for rare idiosyncratic reactions: While not nephrotoxic, azithromycin has rare post-marketing reports of interstitial nephritis—monitor kidney function if unexplained AKI develops 1

Clinical Bottom Line

Both medications can be used safely in patients with existing kidney disease without dose adjustment. If a patient develops AKI while on these medications, look for alternative causes rather than attributing it to the drugs themselves. The evidence consistently demonstrates these agents are not nephrotoxic through direct mechanisms.